Recording of CHI's Webinar "Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models"  is online available now

Webinar Description:

Learn how human cardiac cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro drug discovery & development assays in the pharmaceutical industry. From high-throughput screening (HTS) to toxicology testing, human cardiac cells can be applied in pure 2D cultures for desired controls as well as 3D co-culture systems for physiological relevance. Whether you are screening for new drug targets, or investigating drug effects on electrophysiology, contractility, or cardiac-specific toxicity, this seminar will provide insights for your own research.

Full length recording of the webinar available here

for more details please visit here

 

Cor.4U have electrophysiological parameters approaching adult human tissue

Axiogenesis Cor.4U human cardiomyocytes, serving as a human cellular model in a recent late stage pre-clinical safety study, demonstrated electrophysiological parameters approaching adult human tissue. The use of these Cor.4U cardiomyocytes was “consistent with the emphasis on (Multiple Ion Channel Effects) MICE of the CiPA assay”. The experimental paradigm presented by this study will be amodel for future drug safety screening efforts. 

For more details read the full article here

Application Workshop Material is Available for Download now

We thank our attendees, presenter and cooperation partners for their contribution to the success of this workshop. 

The conference material of our latest Application Workshop "Great Assays For hiPSC-derived Cardiomyocytes & Neurons", Nov 2015  is available here.

Axiogenesis Sublicenses GE Healthcare iPSC Patents

Axiogenesis AG has sublicensed patents from GE Healthcare to commercialize technologies based on human induced pluripotent stem cells (iPSCs). This solidifies the ability for Axiogenesis and its customers to apply Axiogenesis cell types in the development of cellular assays and stem cell-derived disease models for use in drug discovery and toxicity screening. For the complete press release, click here.

FIND US

Nattermannallee 1, Bldg S20
50829 Cologne
Germany – (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)

EMAIL US

Orders: order@axiogenesis.com
Support: support@axiogenesis.com
Other: office@axiogenesis.com

FOLLOW US

Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter

CALL US

Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10